Viridian Therapeutics Q3 EPS $(0.81) Beats $(1.00) Estimate, Sales $25.752K May Not be Comparable To $5.084M Estimate

Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(1.00) by 19 percent. This is a 138.24 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $25.752 thousand which missed the analyst consensus estimate of $5.084 million by 99.49 percent. This is a 63.51 percent decrease over sales of $70.570 thousand the same period last year.